Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Here, I review this remarkable development from the earliest observations of glucose lowering and modest weight losses with native glucagon-like peptide (GLP)-1 and short acting compounds, to the recent development of highly active formulations and new molecules
Additionally, hospitals tend to handle patients with comorbidities such as diabetes and cardiovascular conditions, where GLP-1 drugs provide dual benefits, further driving their use in this setting
R., Nierenberg, A
Koozehchian MS, et al
Int J Obes (Lond) 49(10):19461957
US$ 22.91
US$ 26.26
US$ 21.76
US$ 24.38
